Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, et al
Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Middleton MS, Sirlin CB (2009) Heritability of nonalcoholic fatty liver disease
19:34 - Summary 23:35 - Outro REFERENCES: DeFoor, M
Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
Dosing Framework: Route, Indication, and Evidence Profile The optimal glutathione dose depends on route of administration, clinical goal (antioxidant support, immune function, detoxification), and individual oxidative stress biomarker levels
Advances in Botanical Research